44564
document
Reducing polycystic liver volume in ADPKD : effects of somatostatin analogue octreotide . BACKGROUND AND OBJECTIVES No medical treatment is available for polycystic liver disease , a frequent manifestation of autosomal-dominant polycystic kidney disease ( ADPKD ) . In a prospective , randomized , double-blind , crossover study , 6 months of octreotide ( 40 mg every 28 days ) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD . DESIGN , SETTING , PARTICIPANTS , & MEASUREMENTS In this secondary , post hoc analysis of the above study , octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated . Those analyzing liver and kidney volumes were blinded to treatment . RESULTS Liver volumes significantly decreased from 1595 +/- 478 ml to 1524 +/- 453 ml with octreotide whereas they did not appreciably change with placebo . Changes in liver volumes were significantly different between the two treatment periods ( -71 +/- 57 ml versus +14 +/- 85 ml ) . Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 +/- 431 ml to 1432 +/- 403 ml . Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes ( r = 0.67 ) during octreotide but not during placebo treatment . Liver and kidney volume changes significantly differed with both treatments ( octreotide : -71 +/- 57 ml versus +71 +/- 107 ; placebo : +14 +/- 85 ml versus +162 +/- 114 ) , but net reductions in liver ( -85 +/- 103 ml ) and kidney ( -91 +/- 125 ml ) volume growth on octreotide versus placebo were similar . CONCLUSIONS Octreotide therapy reduces liver volumes in patients with ADPKD and is safe .
44565
Intervention_Pharmacological
somatostatin analogue octreotide
44566
Intervention_Pharmacological
octreotide
44567
Intervention_Control
placebo
44568
Intervention_Pharmacological
octreotide-induced
44569
Intervention_Control
placebo
44570
Intervention_Control
placebo
44571
Intervention_Pharmacological
octreotide
44572
Intervention_Control
placebo
44573
Intervention_Pharmacological
octreotide
44574
Intervention_Pharmacological
Octreotide therapy
44575
Outcome_Physical
polycystic liver volume
44576
Outcome_Physical
liver volumes
44577
Outcome_Physical
liver and kidney volumes
44578
Outcome_Physical
Liver volumes significantly decreased
44579
Outcome_Physical
Changes in liver volumes
44580
Outcome_Other
significantly different
44581
Outcome_Physical
Octreotide-induced liver volume reduction
44582
Outcome_Physical
parenchyma volume
44583
Outcome_Physical
Changes in liver volumes
44584
Outcome_Physical
kidney volumes
44585
Outcome_Physical
Liver and kidney volume changes
44586
Outcome_Other
differed
44587
Outcome_Physical
net reductions in liver
44588
Outcome_Physical
kidney
44589
Outcome_Physical
volume growth
44590
Outcome_Other
similar
44591
Outcome_Physical
liver volumes
44592
Participant_Condition
polycystic liver volume in ADPKD :